Allogeneic bone marrow transplantation in children failing prior autologous bone marrow transplantation

Bone Marrow Transplantation

Volumn 27, Issue 2, 2001, Pages 155-162

  Hale, G A ^a,b   Tong, Xin ^a   Benaim, E ^a,b   Cunningham, J M ^a,b   Heslop, H E ^a,b   Horwitz, E M ^a,b   Leung, W ^a,b   Rochester, R J ^a,b   Shearer, P D ^a,b   Srivastava, D K ^a   Woodard, J P ^a,b   Bowman, L C ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

Allogeneic BMT; Autologous BMT; Graft versus host disease; Second transplant; Survival

Indexed keywords

4 HYDROXYCYCLOPHOSPHAMIDE; BUSULFAN; CARBOPLATIN; CARMUSTINE; CD15 ANTIGEN; CD6 ANTIGEN; CD8 ANTIGEN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; DIMETHYL SULFOXIDE; ETOPOSIDE; GANCICLOVIR; IMMUNOGLOBULIN; INTERLEUKIN 2; MESNA; METHOTREXATE; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; PENTOXIFYLLINE; STEROID; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CAUSE OF DEATH; CHILD; CLINICAL ARTICLE; DONOR; FAMILY; FEMALE; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA REMISSION; LIVER VENOOCCLUSIVE DISEASE; LUNG HEMORRHAGE; MALE; NONHODGKIN LYMPHOMA; OUTCOMES RESEARCH; PNEUMONIA; PRIORITY JOURNAL; SIBLING; TOXICITY; WHOLE BODY RADIATION;

ADOLESCENT; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; LEUKEMIA, MYELOCYTIC, ACUTE; LYMPHOMA, NON-HODGKIN; MALE; RECURRENCE; RETROSPECTIVE STUDIES; SALVAGE THERAPY; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 17744377383     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702765     Document Type: Article

References (56)

1. Outcome for patients with leukemia, multiple myeloma, and lymphoma who relapse after high dose therapy and autologous stem cell support
2. Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: Clinical course and patient follow-up
3. Assessment of the efficacy of purging by using gene marked autologous marrow transplantation for children with AML in first complete remission
4. Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients
5. Escalating sequential high dose carboplatin and etoposide with autologous marrow support in children with relapsed solid tumors
6. Outcomes of transplantation with matched sibling and unrelated-donor bone marrow in children with leukemia
7. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors
8. Response of steroid-resistant graft-versus-host disease to lymphoblast antibody CBL1
9. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr virus-related lymphoproliferation
10. Nonparametric estimation from incomplete observations
11. The analysis of failure times in the presence of competing risks
12. Follow-up report on the outcome of patients relapsing after autologous marrow transplantation for malignant lymphoma
13. Allogeneic bone marrow transplantation for recurrence of leukemia after autologous bone marrow transplantation
14. Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total-body irradiation-containing regimens
15. Second HLA-identical sibling transplants for leukemia recurrence
16. Allogeneic bone marrow transplantation in patients who relapse after autologous transplantation
17. Unrelated donor stem cell transplantation after autologous transplantation: Experience of a single center
18. Partially mismatched related donor transplants as salvage therapy for patients with refractory leukemia who relapse post-BMT
19. Relapse of leukemia after bone marrow transplantation: Effect of second myeloablative therapy
20. Role of second bone marrow transplants
21. Second allogeneic transplantation after failure of first autologous transplantation
22. Allogeneic bone marrow transplant or second autograft in patients with acute leukemia who relapse after an autograft
23. Second allogeneic hematopoietic stem cell transplantation as treatment for leukemia relapsing following a first transplant
24. Second transplant for leukemic relapse after bone marrow transplantation: High early mortality but favorable effect of chronic GVHD on continued remission
25. Cytokine dysregulation as a mechanism of graft-versus-host disease
26. Leukemia relapse after allogeneic bone marrow transplantation: A review
27. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: Increased risk of relapse associated with T-cell depletion
28. Venocclusive disease of the liver and multiorgan failure after bone marrow transplantation: A cohort study of 355 patients
29. Marrow transplantation for patients with thalassemia: Results in class 3 patients
30. Interstitial pneumonitis after bone marrow transplantation: Assessment of risk factors
31. Noninfectious pulmonary disease in the immunocompromised host
32. Idiopathic interstitial pneumonia following marrow transplantation: The relationship with total body irradiation
33. A comparison of single-dose and fractionated total-body irradiation on the development of pneumonitis following bone marrow transplantation
34. The Japanese multicenter open randomized trial of ursodeoxycholic acid prophylaxis for hepatic veno-occlusive disease after stem cell transplantation
35. Pentoxyfylline, ciprofloxacin, and prednisone failed to prevent transplant-related toxicities in bone marrow transplant recipients and were associated with an increased incidence of infectious complications
36. Phase II trial of heparin prophylaxis for veno-occlusive disease of the liver in children undergoing bone marrow transplantation
37. A phase I/II study of prostaglandin E1 for the prevention of hepatic venocclusive disease after bone marrow transplantation
38. A pilot study of continuous infusion heparin for the prevention of hepatic veno-occlusive disease after bone marrow transplantation
39. Does early treatment with high-dose methylprednisolone alter the course of hepatic regimen-related toxicity?
40. Phase I-II trial of pentoxifylline for the prevention of transplant-related toxicities following bone marrow transplantation
41. Treatment of severe veno-occlusive disease with defibrotide: Compassionate use results in response without significant toxicity in a high-risk population
42. A randomized placebo-controlled trial of lysofylline in HLA-identical, sibling-donor, allogeneic bone marrow transplant recipients
43. Treatment of acute myelogenous leukemia: An EBMT-EORTC retrospective analysis of chemotherapy versus allogeneic or autologous bone marrow transplantation
44. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: Results of AML 10 trial
45. Autologous stem cell transplantation in acute myeloid leukemia
46. Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood
47. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma
48. Development of a marrow transplant regimen for acute leukemia using targeted hematopoietic irradiation delivered by 131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation
49. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative chemotherapy
50. Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation
51. Transplant-Lite: Induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies
52. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for treatment of malignant and nonmalignant hematologic diseases
53. Second allogeneic stem cell transplantation using nonmyeloablative conditioning for patients who relapsed or developed secondary malignancies following autologous transplantation
54. Genetic polymorphisms of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia
55. Pharmacogenomics: Translating functional genomics into rational therapeutics
56. Recipient tumor necrosis factor-A and interleukin-10 gene polymorphisms associate with early mortality and acute graft-versus-host disease severity in HLA-matched sibling bone marrow transplants